The Paper That Coined the 'Entourage Effect' — and What It Actually Meant
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
Bottom Line
Inactive lipids that accompany the endocannabinoid 2-AG in the body amplify its signal at cannabinoid receptors. The 'entourage effect' was originally about endogenous biochemistry, not cannabis terpenes.
Why It Matters
Coined the term 'entourage effect' and established that endocannabinoid signaling depends on biological context, not just the signaling molecule itself. Proposed a new route for molecular regulation of cannabinoid activity. The concept was later extended to cannabis phytochemistry and became the most influential idea in the cannabis industry.
The Backstory
The word that launched a billion dollars of marketing started as a quiet observation about fat molecules in a Jerusalem laboratory.
In 1998, Shimon Ben-Shabat — a PhD student working in Raphael Mechoulam's lab at the Hebrew University — noticed something strange about 2-AG, the endocannabinoid his group had helped identify three years earlier. In the body, 2-AG was never alone. It was always accompanied by two other lipid molecules — 2-linoleoyl-glycerol and 2-palmitoyl-glycerol. Structurally similar, but pharmacologically silent. They didn't bind cannabinoid receptors. They didn't activate anything. By every standard measure, they were inactive.
But when Ben-Shabat tested 2-AG with its companions present, the active molecule worked better. Stronger binding. Greater enzyme inhibition. Enhanced behavioral effects in mice. The inactive compounds were amplifying the active one.
He and Mechoulam gave this phenomenon a name: the entourage effect.
It was a precise, technical observation about endogenous lipid biochemistry. It would become the most marketable concept in cannabis history.
What They Actually Found
The finding was elegant and unexpected. The body wasn't just making 2-AG — it was making 2-AG packaged with helper molecules that boosted its signal. The endocannabinoid system had built-in amplifiers.
Inactive alone, amplifying together
2-linoleoyl-glycerol and 2-palmitoyl-glycerol do not bind CB1 or CB2 receptors and produce no cannabinoid effects on their own. But in the presence of 2-AG, they significantly potentiate its receptor binding, enzyme inhibition, and in vivo behavioral effects. The mechanism was proposed as a 'novel route for molecular regulation of endogenous cannabinoid activity.'
This is different from simple synergy (two active compounds working together). This is inactive compounds enhancing an active one — a subtler, more surprising form of biological cooperation.
Ben-Shabat et al. (1998), Eur J Pharmacol 353:23-31
The Team
The paper had ten authors spanning two continents. At its center was Mechoulam's lab in Jerusalem — the same lab that had isolated THC in 1964, discovered anandamide in 1992, and co-identified 2-AG in 1995.
Shimon Ben-Shabat was the first author — Mechoulam's PhD student who would go on to become a professor at Ben-Gurion University of the Negev. His doctoral work focused on the biochemistry of endocannabinoids, and this paper emerged from his close study of what accompanied 2-AG in biological extracts.
Raphael Mechoulam was the senior author, now in his late sixties, still producing landmark findings. The entourage effect concept was characteristic of his approach: instead of focusing on a single molecule in isolation, he asked what the molecule's biological context looked like.
The author list also included Ester Fride (behavioral pharmacology), Zvi Vogel (receptor biology), and a Naples contingent — Tiziana Bisogno, Luciano De Petrocellis, and Vincenzo Di Marzo — who were among the world's leading endocannabinoid biochemists. The Italian collaboration brought expertise in lipid metabolism and endocannabinoid synthesis pathways.
The funding came from NIDA (grant DA 9789) — the same NIH institute that had funded much of Mechoulam's career in endocannabinoid discovery.
What "Entourage" Actually Meant
The paper's title was precise: "An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity."
Every word matters:
- Inactive — the companion molecules do nothing on their own
- Endogenous — the body makes them, alongside 2-AG
- Fatty acid glycerol esters — structurally specific lipids, not random compounds
- Enhance — they amplify, not replace, the active molecule's effects
The "entourage" was a metaphor: 2-AG travels with a retinue. The supporting cast doesn't perform but makes the star's performance better.
Myth vs. Reality
The entourage effect was originally about cannabis terpenes and cannabinoids working together.
The original 1998 entourage effect had nothing to do with cannabis plants, terpenes, or cannabinoids working together. It described how inactive endogenous lipids in the body enhance the activity of the endocannabinoid 2-AG. The concept was later extended to cannabis phytochemistry by Russo in 2011, who proposed that plant terpenes might similarly enhance plant cannabinoids. This extension — from endogenous lipids to plant compounds — is a hypothesis, not a finding. The original entourage effect is about the body's own biochemistry.
The Evidence
Ben-Shabat et al. (1998) studied 2-AG and its endogenous fatty acid glycerol ester companions. No plant-derived compounds were involved. Russo (2011) explicitly extended the concept to phytocannabinoid-terpenoid interactions in his 'Taming THC' review.
Ben-Shabat et al. (1998), Eur J Pharmacol 353:23-31; Russo (2011), Br J Pharmacol 163:1344-1364
Why Inactive Compounds Matter
The finding opened a window into how the endocannabinoid system actually regulates itself. If 2-AG's effects depend on what's around it, then measuring 2-AG levels alone doesn't tell you how strong the signal actually is. The system has a built-in volume control that depends on the presence of non-signaling lipids.
This has implications for pharmaceutical development. If you want to boost endocannabinoid signaling, you don't necessarily need more 2-AG — you might just need to preserve its entourage. FAAH and MAGL inhibitors (which prevent endocannabinoid degradation) are one approach. But another, suggested by this paper, is to ensure the companion esters remain intact alongside 2-AG.
From Endogenous Biology to Cannabis Marketing
The conceptual leap from Ben-Shabat's endogenous lipid observation to cannabis industry marketing happened in stages:
The irony is that the original entourage effect — endogenous lipids potentiating endogenous cannabinoids — is well-supported experimental science. The extended version — plant terpenes potentiating plant cannabinoids — is a hypothesis that hasn't been consistently confirmed. The marketing appropriated the credibility of the original to sell the unproven extension.
What We Still Don't Know
Twenty-five years after publication, several questions remain:
Mechanism: How exactly do 2-Lino-Gl and 2-Palm-Gl potentiate 2-AG? Proposed mechanisms include enzyme competition (protecting 2-AG from MAGL degradation), membrane effects (changing local lipid environment around receptors), and allosteric modulation. None has been definitively confirmed.
Generalizability: Does the entourage principle apply to anandamide and its companion lipids? To other lipid signaling systems beyond endocannabinoids? The paper proposed it as a "novel route for molecular regulation" — suggesting it might be a general biological principle.
Clinical relevance: Could measuring entourage ester levels alongside 2-AG provide better biomarkers for endocannabinoid deficiency? If 2-AG levels look normal but companion ester levels are depleted, the effective signal could still be deficient.
Frequently Asked Questions
Cite this study
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. https://doi.org/10.1016/s0014-2999(98)00392-6